These findings suggest that loss of expression of IGFBPs in adenocarcinomas increases IGF signalling and its functional consequences, processes clearly associated with the clinical phenotypes of ovarian adenocarcinomas. The gene discussed is IGF1; the disease is adenocarcinoma.